# Section 1: Company Overview

## S1.1: Basic Information

| Field | Value |
| :---- | :---- |
| Company Name | PolyNovo Limited |
| Establishment Date | N/A |
| Headquarters Location | Port Melbourne, Australia |


## S1.2 : Core Competencies

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Innovation Advantages | PolyNovo demonstrates innovation advantages through its dedicated Research and Development team that supports new and innovative uses for its products, including the development of implantable devices and line extensions such as NovoSorb MTX and its variants. The company leverages surgeon insights to drive its product pipeline and invests in professional education programs like 'Science of Complex Wound Management' to train clinicians. Manufacturing processes and technology are shared across product lines, including the NovoSorb SynTrix platform for plastics and reconstructive devices, and the company is expanding manufacturing capacity with a new modular, automated facility expected operational by December 2025. | PolyNovo leverages its proprietary NovoSorb resorbable polymer platform, which offers flexibility in configuration (foams, filaments, films, non-woven and woven structures, thermoplastics), proven biocompatibility, and tailored resorption profiles. The company invests in R&D to support new product development and faster commercialization, including surgeon-led innovation and clinical trials such as the U.S. BARDA pivotal trial and diabetic foot ulcer studies. Manufacturing processes and technology developed for hernia devices are utilized as building blocks for other tissue reinforcement products, with plans for a new co-located manufacturing facility designed for scale, flexibility, modularity, and automation. |
| Product Advantages | PolyNovo's product portfolio centers on the NovoSorb Biodegradable Temporising Matrix (BTM) and its derivatives, including NovoSorb MTX and the NovoSorb SynTrix platform for tissue reinforcement in hernia, breast, orthopaedics, and other applications. The company also holds exclusive sales and distribution rights for SUPRATHEL in the U.K., Australia, and New Zealand, complementing its graftable products with an epidermal substitute. Its products are designed for versatility, robustness against infection, and improved patient outcomes, with significant health economic benefits and suitability for complex wound care across multiple indications including burns, trauma, diabetic ulcers, and surgical wounds. | PolyNovo's product portfolio includes NovoSorb BTM, a biodegradable temporising matrix used for dermal repair in burns, acute and chronic wounds, limb salvage, and other applications, and NovoSorb MTX, a product for partial and full thickness wounds without a sealing membrane, cleared by FDA 510(k). The portfolio is expanding into implantable applications such as hernia repair, breast reconstruction, soft-tissue fillers, tendon repair, and bone regeneration. NovoSorb BTM and MTX are complementary products addressing a broad range of clinical needs in soft tissue reconstruction and wound management. |
| Brand Recognition | PolyNovo is recognized as the category leader in burn procedures in multiple developed markets including the U.S., U.K., Germany, Australia, and New Zealand, with leading market share in difficult burns and soft tissue reconstruction. The company has established long-term relationships with clinicians and health systems globally, supported by a growing sales force and surgeon-driven adoption. Its partnership with BARDA for pivotal clinical trials and its presence in over 41 countries underpin its strong brand positioning. The addition of SUPRATHEL to its portfolio further enhances its market presence in epidermal substitutes. | PolyNovo is recognized as a leader in third degree burns in Australia and New Zealand and has growing presence in the U.S., UK, Germany, Canada, Hong Kong, and India. The company has established long-term relationships with surgeons and hospitals, with over 600 customer accounts globally and a growing direct salesforce. NovoSorb BTM features prominently in major clinical conference presentations worldwide and benefits from surgeon-to-surgeon referrals. The company is regarded as the next generation standard of care for burn care by clinicians. |
| Reputation Ratings | PolyNovo maintains a robust ESG framework with carbon-neutral certification for its Australian operations in FY23 and a commitment to environmental sustainability through low-emission manufacturing and waste management programs. The company upholds high standards in corporate governance aligned with ASX Corporate Governance Council principles, including policies on ethics, diversity, modern slavery, and health and safety. It reports zero lost time injuries in FY24 and actively manages risks related to product liability, intellectual property, and regulatory compliance. The company also adheres to best practice bioethics in clinical trials and animal testing. | PolyNovo is carbon neutral certified for its business operations for FY2021-22, with its manufacturing process being low emitting. The company maintains a robust ESG framework, including Environment, Social, and Governance policies, and has zero lost time injuries and medical treatment injuries reported in FY23. PolyNovo upholds best-practice bioethics principles, complies with modern slavery laws, and uses environmentally certified waste disposal providers. Corporate governance aligns with the ASX Corporate Governance Council's eight Principles of Good Corporate Governance. |


## S1.3 : Mission & Vision

| Field | Value |
| :---- | :---- |
| Mission Statement | Our mission is to innovate and bring disruptive technologies to market by partnering with the best minds to improve patient outcomes and reimagine the standard of care. |
| Vision Statement | Healing. Redefined. |
| Core Values | We put patients first, We earn trust, We innovate boldly, We believe in each other, We respect and nurture diversity |


# Section 2: Financial Performance

## S2.1: Income Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Revenue | 104,763.0 | 66,536.0 | 41,890,603.0 | Thousands | AUD |
| Cost of Goods Sold | 5,479.0 | (4,433,696.0) | (2,202,686.0) | Thousands | AUD |
| Gross Profit | 99,284.0 | 70,968,681.0 | 44,093,289.0 | Thousands | AUD |
| Operating Expense | 94,592.0 | (66,420,115.0) | (39,421,500.0) | Thousands | AUD |
| Operating Income | 2,432.0 | (4,219.0) | (1,150,924.0) | Thousands | AUD |
| Net Profit | 5,261.0 | (4,924.0) | (1,192,532.0) | Thousands | AUD |
| Income before income taxes | 1,711.0 | (4,933.0) | (1,150,924.0) | Thousands | AUD |
| Income tax expense(benefit) | (3,550.0) | (9.0) | (41,608.0) | Thousands | AUD |
| Interest Expense | 721.0 | 714.0 | 315,366.0 | Thousands | AUD |


## S2.2: Balance Sheet

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Total Assets | 108,720.0 | 92,621.0 | 34,971,530.0 | Thousands | AUD |
| Current Assets | 79,295.0 | 67,354.0 | 16,189,509.0 | Thousands | AUD |
| Non-Current Assets | 29,425.0 | 25,267.0 | 18,782,021.0 | Thousands | AUD |
| Total Liabilities | 36,596.0 | 27,238.0 | 17,256,444.0 | Thousands | AUD |
| Current Liabilities | 23,247.0 | 12,668.0 | 7,756,293.0 | Thousands | AUD |
| Non-Current Liabilities | 13,349.0 | 14,570.0 | 9,500,151.0 | Thousands | AUD |
| Shareholders' Equity | 72,124.0 | 65,383.0 | 17,715,086.0 | Thousands | AUD |
| Retained Earnings | N/A | 121,378,312.0 | 116,453,773.0 | Thousands | AUD |
| Total Equity and Liabilities | 108,720.0 | 92,620,649.0 | 34,971,530.0 | Thousands | AUD |
| Inventories | 8,972.0 | 4,530.0 | 2,535,293.0 | Thousands | AUD |
| Prepaid Expenses | 3,301.0 | 1,903.0 | 1,261,988.0 | Thousands | AUD |


## S2.3: Cash Flow Statement

| Field | 2024 | 2023 | 2022 | Multiplier | Currency |
| :---- | :---- | :---- | :---- | :---- | :---- |
| Net Cash Flow from Operations | 3,683.0 | 6,613.0 | 2,057,034.0 | Thousands | AUD |
| Net Cash Flow from Investing | 1,490.0 | 849.0 | N/A | Thousands | AUD |
| Net Cash Flow from Financing | 3,170.0 | 48,064.0 | N/A | Thousands | AUD |
| Net Increase/Decrease in Cash | (977.0) | 40,602.0 | N/A | Thousands | AUD |
| Dividends | N/A | 0.0 | 0.0 | Thousands | AUD |


## S2.4: Key Financial Metrics

|       | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Gross Margin | 94.77% | 6763.60% | 105.26% |
| Operating Margin | 2.32% | (6.34%) | (2.75%) |
| Net Profit Margin | 5.02% | (7.40%) | (2.85%) |
| Current Ratio | 341.10% | 531.69% | 208.73% |
| Quick Ratio | 288.30% | 480.90% | 159.77% |
| Debt-to-Equity | 50.74% | 41.66% | 97.41% |
| Interest Coverage | 337.31% | (590.90%) | (364.95%) |
| Asset Turnover | 104.07% | 0.38% | N/A |
| Return on Equity | 7.65% | (0.06%) | N/A |
| Return on Assets | 5.23% | (0.03%) | N/A |
| Effective Tax Rate | (207.48%) | 0.18% | 3.62% | 
| Dividend Payout Ratio | N/A | -0.00% | -0.00% |


## S2.5: Operating Performance

| Field | 2024 | 2023 | 2022 |
| :---- | :---- | :---- | :---- |
| Revenue by Product/Service | BARDA revenue: $11,150,000, Commercial product sales: $92,042,000 | BARDA revenue: $5,663,000, Commercial product sales: $59,578,000 | BARDA revenue: $3,796,679, Commercial product sales: $37,643,160 |
| Revenue by Geographic Region | United States of America: $79,836,000, Australia and New Zealand: $6,560,000, Other countries: $16,796,000 | United States of America: $51,764,000, Australia and New Zealand: $4,769,000, Other countries: $8,709,000 | United States of America: $35,857,273, Australia and New Zealand: $3,206,724, Other countries: $2,375,842 |


# Section 3: Business Analysis

## S3.1: Profitability Analysis

| Field | Answer |
| :---- | :---- |
| Revenue & Direct-Cost Dynamics | PolyNovo Limited's revenue shows a significant decline from 41,890,603 AUD in 2022 to 66,536 AUD in 2023, then a moderate increase to 104,763 AUD in 2024. Despite this, the gross margin remains exceptionally high and volatile, with 105.26% in 2022, an anomalous spike to 6763.60% in 2023, and a more normalized 94.77% in 2024. Revenue by product/service indicates steady growth in BARDA revenue from 3,796,679 AUD in 2022 to 11,150,000 AUD in 2024, and commercial product sales also increased from 37,643,160 AUD in 2022 to 92,042,000 AUD in 2024. Geographically, the United States remains the dominant market, growing from 35,857,273 AUD in 2022 to 79,836,000 AUD in 2024, with Australia and New Zealand and other countries also showing growth but at a smaller scale. |
| Operating Efficiency | Operating margin improved from a negative (2.75%) in 2022 to a positive 2.32% in 2024, after a dip to (6.34%) in 2023. Operating income moved from a loss of (1,150,924) AUD in 2022 to a small profit of 2,432 AUD in 2024, reflecting improved operational control. Operating expenses, while large in absolute terms, show a reduction in negative values from (39,421,500) AUD in 2022 to 94,592 AUD in 2024, indicating better cost management or possible data irregularities. The ratio of operating income to revenue improved, signaling enhanced efficiency despite the revenue fluctuations. |
| External & One-Off Impact | The effective tax rate shows significant volatility, from 3.62% in 2022 to 0.18% in 2023, then a negative (207.48%) in 2024, which suggests unusual tax benefits or adjustments impacting net profitability. Income tax expense also fluctuates, with a negative tax expense of (3,550) AUD in 2024, indicating tax credits or refunds. No explicit non-recurring items or external factors affecting profitability are listed in the provided data. |


## S3.2: Financial Performance Summary

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Comprehensive financial health | In 2024, PolyNovo Limited demonstrated an improved financial position compared to 2023. Total assets increased from AUD 92,621 thousand to AUD 108,720 thousand, driven by growth in both current assets (from AUD 67,354 thousand to AUD 79,295 thousand) and non-current assets (from AUD 25,267 thousand to AUD 29,425 thousand). Total liabilities rose from AUD 27,238 thousand to AUD 36,596 thousand, primarily due to a significant increase in current liabilities (from AUD 12,668 thousand to AUD 23,247 thousand), while non-current liabilities slightly decreased. Shareholders' equity strengthened from AUD 65,383 thousand to AUD 72,124 thousand, reflecting retained earnings and net profit improvements. The current ratio decreased from 531.69% to 341.10%, indicating a reduction in liquidity but still a strong ability to cover short-term obligations. The debt to equity ratio increased from 41.66% to 50.74%, suggesting a modest rise in leverage but still a moderate capital structure. Overall, the company’s financial health in 2024 shows growth in asset base and equity with manageable increases in liabilities and solid liquidity levels. | In 2023, PolyNovo Limited's total assets stood at AUD 92,621 thousand, a significant decrease from AUD 34,971,530 thousand in 2022, indicating a major contraction in asset base. Current assets were AUD 67,354 thousand, and non-current assets were AUD 25,267 thousand, showing a shift towards a smaller scale of operations or asset reclassification. Total liabilities decreased to AUD 27,238 thousand from AUD 17,256,444 thousand in 2022, with current liabilities at AUD 12,668 thousand and non-current liabilities at AUD 14,570 thousand. Shareholders' equity was AUD 65,383 thousand, down from AUD 17,715,086 thousand in 2022, but retained earnings increased to AUD 121,378,312 thousand from AUD 116,453,773 thousand, suggesting accumulated profits or adjustments. The current ratio improved markedly to 531.69% from 208.73%, indicating strong short-term liquidity. The debt to equity ratio improved to 41.66% from 97.41%, reflecting a more conservative capital structure with less reliance on debt financing. Overall, the company shows a smaller but more liquid and less leveraged financial position in 2023 compared to 2022. |
| Profitability and earnings quality | PolyNovo Limited’s profitability improved markedly in 2024. Revenue surged by approximately 57.5% from AUD 66,536 thousand in 2023 to AUD 104,763 thousand in 2024, supported by higher BARDA revenue (from AUD 5,663 thousand to AUD 11,150 thousand) and commercial product sales (from AUD 59,578 thousand to AUD 92,042 thousand). Gross profit increased to AUD 99,284 thousand from AUD 70,968 thousand, with gross margin decreasing from an anomalously high 6763.60% in 2023 to a more realistic 94.77% in 2024, indicating improved cost of goods sold reporting and strong profitability. Operating income turned positive at AUD 2,432 thousand compared to a loss of AUD 4,219 thousand in 2023, with operating margin improving from -6.34% to 2.32%. Net profit reversed from a loss of AUD 4,924 thousand to a profit of AUD 5,261 thousand, yielding a net profit margin of 5.02%. Return on equity and assets also improved significantly to 7.65% and 5.23%, respectively, reflecting enhanced earnings quality and efficient use of capital. The effective tax rate was negative at -207.48%, driven by a tax expense of AUD 3,550 thousand despite positive income before taxes, which may indicate deferred tax or tax adjustments affecting net profit quality. | Revenue for 2023 was AUD 66,536 thousand, up from AUD 41,890,603 thousand in 2022, indicating a substantial reduction in reported revenue scale but an improvement in revenue quality or reporting basis. Cost of goods sold increased to AUD -4,433,696 thousand from AUD -2,202,686 thousand, yet gross profit rose significantly to AUD 70,968,681 thousand from AUD 44,093,289 thousand, resulting in an extraordinary gross margin of 6763.60% compared to 105.26% in 2022, which may reflect accounting or classification changes. Operating expenses were AUD -66,420,115 thousand, up from AUD -39,421,500 thousand, leading to an operating loss of AUD -4,219 thousand, improved from a loss of AUD -1,150,924 thousand in 2022. Net profit was a loss of AUD -4,924 thousand, better than the AUD -1,192,532 thousand loss in 2022. Operating margin and net profit margin worsened to -6.34% and -7.40% respectively, from -2.75% and -2.85%, indicating profitability challenges despite higher gross profit. Return on equity and assets were negative at -0.06% and -0.03%, respectively, reflecting low earnings relative to invested capital. Overall, profitability remains negative but with signs of reduced losses and improved gross profitability. |
| Operational efficiency | Operational efficiency showed mixed results in 2024. While revenue and gross profit increased substantially, operating expenses remained high at AUD 94,592 thousand, close to gross profit levels, which constrained operating income to a modest AUD 2,432 thousand. Asset turnover improved dramatically from 0.38% in 2023 to 104.07% in 2024, indicating much better utilization of assets to generate revenue. Inventories doubled from AUD 4,530 thousand to AUD 8,972 thousand, which may suggest increased production or stockpiling to meet demand. Net cash from operations declined from AUD 6,613 thousand to AUD 3,683 thousand, signaling some challenges in converting earnings into cash flow. Working capital increased as current assets grew faster than current liabilities, but the current ratio decreased, reflecting higher current liabilities. Net cash from investing activities increased to AUD 1,490 thousand, indicating ongoing investment, while net cash from financing activities dropped sharply to AUD 3,170 thousand from AUD 48,064 thousand, suggesting reduced external financing reliance. Overall, operational efficiency improved in asset utilization but cash flow generation from operations weakened. | Cost control appears challenging as operating expenses increased substantially to AUD 66,420,115 thousand in 2023 from AUD 39,421,500 thousand in 2022, outpacing revenue growth. Asset turnover was 0.38 in 2023, indicating moderate utilization of assets to generate revenue. Inventories increased to AUD 4,530 thousand from AUD 2,535,293 thousand, suggesting inventory management changes or scale adjustments. Net cash from operations was AUD 6,613 thousand, a decrease from AUD 2,057,034 thousand in 2022, indicating reduced cash generation from core business activities. Net cash from investing was positive at AUD 849 thousand, and net cash from financing was AUD 48,064 thousand, contributing to a net increase in cash of AUD 40,602 thousand. Working capital remains strong given the high current ratio, supporting operational liquidity. Overall, operational efficiency shows mixed signals with increased costs and lower cash from operations but strong liquidity and cash inflows from financing. |
| Financial risk identification and early warning | Financial risk indicators in 2024 show some areas of concern. The debt to equity ratio increased to 50.74% from 41.66%, indicating higher leverage and potential increased financial risk. The current ratio, while still strong at 341.10%, declined significantly from 531.69%, reflecting increased current liabilities that may pressure short-term liquidity. Interest expense remained stable at AUD 721 thousand, but interest coverage ratio improved substantially to 337.31% from a negative figure in 2023, indicating better ability to service interest obligations from operating income. The effective tax rate was negative at -207.48%, which is unusual and may reflect tax credits or adjustments that could pose risks if not sustainable. The increase in inventories and current liabilities could signal working capital management risks. Overall, while leverage and liquidity remain manageable, the company should monitor tax-related anomalies and working capital dynamics to mitigate financial risks. | Leverage risk has decreased as debt to equity ratio improved to 41.66% from 97.41% in 2022, indicating reduced financial risk from lower relative debt levels. Liquidity risk is low given the very high current ratio of 531.69%, suggesting ample current assets to cover current liabilities. Interest expense increased slightly to AUD 714 thousand from AUD 315,366 thousand, but interest coverage ratio remains negative at -590.90%, indicating operating losses are insufficient to cover interest expenses comfortably. The effective tax rate dropped sharply to 0.18% from 3.62%, reflecting minimal tax burden or losses carried forward. The negative operating and net margins, along with negative returns on equity and assets, signal ongoing profitability risk. No dividends were paid, indicating a conservative cash distribution policy. Overall, financial risk is mitigated by strong liquidity and lower leverage but remains elevated due to persistent losses and negative interest coverage. |
| Future financial performance projection | Looking ahead, PolyNovo Limited’s future financial performance appears cautiously optimistic. The company increased investments as indicated by higher net cash used in investing activities (AUD 1,490 thousand), which may support growth initiatives. Reduced net cash from financing activities (AUD 3,170 thousand) suggests a shift towards internal funding or reduced external borrowing. The absence of dividends in 2024 and no data on retained earnings may imply a focus on reinvestment rather than shareholder payouts. Revenue growth was broad-based geographically, with the United States revenue increasing from AUD 51,764 thousand to AUD 79,836 thousand, Australia and New Zealand from AUD 4,769 thousand to AUD 6,560 thousand, and other countries from AUD 8,709 thousand to AUD 16,796 thousand, indicating expanding market penetration. The strong improvement in profitability and asset turnover supports sustainable cash flow generation, though operational cash flow declined. The company should continue to monitor working capital and tax positions to ensure cash flow sustainability. Overall, investment activity and geographic diversification position PolyNovo for continued growth, but cash flow management and risk mitigation will be critical. | Investment activity in 2023 shows a positive net cash flow from investing of AUD 849 thousand, suggesting some asset disposals or returns on investments. Financing activities generated significant cash inflows of AUD 48,064 thousand, which supported a net increase in cash of AUD 40,602 thousand, indicating strong financing support for operations or growth. No dividends were declared, implying retention of earnings for reinvestment or liquidity preservation. Revenue by product shows growth in BARDA revenue to AUD 5,663,000 and commercial product sales to AUD 59,578,000, indicating diversified and expanding revenue streams. Geographically, the United States remains the largest market at AUD 51,764,000, with growth also in Australia/New Zealand and other countries, suggesting geographic expansion. Cash flow sustainability depends on continued financing and operational improvements. The company appears positioned for potential growth with strong liquidity and financing but must improve profitability and operational efficiency to ensure long-term financial performance. |


## S3.3: Business Competitiveness

| Field | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Business Model | PolyNovo Limited operates primarily as a developer, manufacturer, and seller of innovative medical devices based on its proprietary bioabsorbable polymer technology called NovoSorb. The company's primary revenue generation comes from the sale of its flagship product, NovoSorb Biodegradable Temporising Matrix (BTM), a dermal scaffold used for dermis regeneration in cases of extensive surgery, trauma, or burns. Revenue is recognized at the point in time when control of the product transfers to the customer, either directly or through distributors in certain overseas territories. The company also generates revenue from research and development services, notably through a contract with the Biomedical Advanced Research and Development Authority (BARDA) in the U.S., where revenue is recognized over time based on progress in clinical studies and trial tasks. PolyNovo's business model includes direct sales in key markets such as Australia, Hong Kong, India, Ireland, New Zealand, Singapore, the United Kingdom, and the United States, and distributor sales in Canada, Europe, Taiwan, and South Africa. The company invests in research and development to expand its product range, including new sizes and variants of NovoSorb BTM and other derivative products like NovoSorb MTX and implantable devices. Manufacturing is conducted primarily at its Port Melbourne facility, with plans for a third manufacturing facility to increase production capacity. The company also benefits from government grants and interest income from cash deposits. Overall, PolyNovo's business model is centered on product sales of proprietary medical devices, supported by ongoing R&D services and strategic partnerships. | PolyNovo operates primarily as a designer, manufacturer, and seller of biomedical devices based on its proprietary NovoSorb bioabsorbable polymer technology. The company's main revenue stream is commercial product sales, particularly of its flagship product NovoSorb BTM, which is used in burns, acute and chronic wounds, limb salvage, necrotising fasciitis, and other tissue repair applications. Revenue is recognized at the point of delivery to customers or distributors, with the company acting as principal in sales to distributors. Additionally, PolyNovo generates revenue from research and development services under contracts such as with BARDA, where revenue is recognized over time based on progress in clinical and trial tasks. The company also receives government grants supporting manufacturing and development activities. Key products include NovoSorb BTM and NovoSorb MTX, with ongoing R&D to expand indications and product portfolio. The business model focuses on direct sales in key markets (U.S., Australia, UK, Europe) and distributor sales in other territories, supported by clinical education and surgeon engagement. The company invests heavily in R&D, manufacturing capacity expansion, and sales team growth to drive commercialisation and global market penetration. |
| Market Position | PolyNovo is a market leader in the category of burn procedures in several developed markets worldwide, including Australia, New Zealand, the United Kingdom, Germany, and the United States. The company holds the leading market share in difficult burns and soft tissue reconstruction procedures in these regions. For example, in the U.K., NovoSorb BTM is used in all 24 burns units and 22 major treatment centers, making the business profitable and the market leader for full-thickness burns. In Germany, the company has penetrated 98% of burn centers and is experiencing strong growth in indications beyond full-thickness burns. The U.S. market is the company's largest and fastest-growing market, with sales growth of 49.0% in AUD (45.6% in USD) in FY24, driven by organic growth and new account acquisitions. The BARDA pivotal trial in the U.S. supports regulatory approval efforts and reimbursement expansion. Rest of World (ROW) sales grew 73.3% in AUD, with notable growth in Australia (38.7%), U.K./Ireland (81.5%), Germany (81.2%), and Hong Kong (107.2%). The company is expanding its geographic footprint with regulatory approvals and distributor appointments in markets such as Peru, Bolivia, Ecuador, Thailand, Sri Lanka, Mexico, and India, where NovoSorb BTM was included in the Government-e-Marketplace portal to facilitate government hospital procurement. PolyNovo is also targeting entry into Japan, China, and Brazil. The company has a strong clinical evidence base with over 280 published articles and abstracts supporting NovoSorb BTM. Its competitive advantages include patented proprietary technology with superior design flexibility, bioabsorption, and biocompatibility, a growing product portfolio, and a strong sales and clinical education force. Overall, PolyNovo is positioned as a market leader in its core burn care markets and is expanding its presence and product applications globally. | PolyNovo is a market leader in the burns segment in Australia and New Zealand and has achieved market leadership in burns in the UK. The company has demonstrated strong sales growth globally, with FY23 NovoSorb BTM sales up 58.3% year-on-year. The U.S. market sales grew 44.6% in AUD, and Rest of World (ROW) sales increased by 133.9%, including significant growth in Australia (84.3%), UK/Ireland (168.8%), Germany (192.8%), Canada, Hong Kong, and new entries into India, Spain, and France. The company has expanded its direct customer accounts from 470 to 638 hospitals globally, including increasing U.S. accounts from 189 to 299. Distribution partners cover Europe with strong presence in Germany (98% of burn centres) and expanding footprint in France, Spain, and UAE. PolyNovo's competitive advantages include proprietary patented technology with no royalty obligations, surgeon-led innovation, strong clinical evidence, and a growing product portfolio with FDA 510(k) clearance for NovoSorb MTX. The company is positioned as a market leader in burns and is expanding into soft tissue reconstruction and other indications, targeting a total addressable market expansion. The BARDA pivotal trial and other clinical studies support its competitive standing. Overall, PolyNovo is a market leader in key segments and geographies, with rapid growth and expanding global reach. |


# Section 4: Risk Factors

## S4.1: Risk Factors

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Market Risks | PolyNovo faces market risks including increased competition which may lead to loss of market share, and the risk that their products could be superseded by medical advancements resulting in alternative products or treatments. Demand volatility is implied through the need to expand product ranges and enter new geographical markets. Inflation and rising interest rates have increased costs in all markets, including wages and salaries, impacting operational costs. The Company is exposed to external market factors such as regulatory approvals required for new markets and products, and geopolitical risks as evidenced by demand in war zones like Ukraine and the Middle East. The Company mitigates these risks by strategic product development reviews, evolving product roadmaps supported by R&D, expanding geographical footprint, and entering new markets with regulatory approvals in progress. | PolyNovo faces market risks including volatility in demand and competition in the biotechnology and medical device sectors. The company operates in multiple international markets including the U.S., Australia, UK, India, Canada, Hong Kong, Spain, and France, with expansion plans into China and Japan. Market conditions such as inflation and rising interest rates have increased costs including wages and salaries. The biotechnology sector is inherently high risk and volatile, with investment in research and development projects being speculative. The success of research projects and ability to attract funding are uncertain, impacting future commercialisation. The company is exposed to foreign currency risk due to operations and transactions in multiple currencies (USD, NZD, EUR, CAD, INR, GBP, SGD, HKD), which can affect financial results. PolyNovo mitigates foreign currency risk by maintaining cash and equivalents in multiple currencies and matching receivables and payables in those currencies. The company also faces risks from rapid advancements in technology and uncertainty of patent protection and proprietary rights. The company manages market risk by expanding sales teams, entering new markets, launching new products, and leveraging surgeon-led innovation and partnerships. |
| Operational Risks | Operational risks include concentration of manufacturing at a single site which could disrupt supply if the site becomes inoperative; reliance on suppliers for key materials which may cause delays or disruptions; risks related to product quality that could lead to injury, litigation, recall, and reputational harm; and risks to intellectual property through hacking or employee misconduct. The Company mitigates manufacturing risks by constructing a third manufacturing facility, implementing business continuity plans, maintaining business interruption insurance, and storing finished products in multiple offsite warehouses. Supplier risks are managed by close collaboration with suppliers, inventory management, and diversification of suppliers. Product liability risks are mitigated through quality focus across design, testing, manufacturing, and post-market monitoring, collaboration with clinicians, and product liability insurance. Intellectual property risks are managed via confidentiality agreements, limited and monitored system access, an evolving patent and trademark portfolio, and external legal counsel for litigation management. Additionally, the Company invests in professional education, clinical evidence building, and expanding product lines to support operational growth. | Operational risks include challenges in manufacturing, supply chain, and business continuity. PolyNovo has commissioned a second manufacturing facility and is designing a new co-located manufacturing facility to support scale and flexibility. The company faces risks related to product development and quality, especially inherent in biotechnology product development where clinical trials may fail to demonstrate safety or efficacy. The company invests in R&D and clinical trials to support new product development and faster commercialisation. Operational risks also arise from the need to recruit and onboard skilled personnel, as evidenced by the expansion of sales and clinical teams globally. The company manages operational risks through formal risk management policies, ongoing monitoring, and investment in enabling functions such as HR, IT, and legal. Health and safety risks are managed with a strong focus on injury prevention and continuous improvement, with zero lost time injuries reported in FY23. The company also faces risks related to inventory management and allocation of manufacturing variances. Business continuity is supported by cash flow forecasting and discretion in managing cash outflows in response to changing conditions. |
| Financial Risks | Financial risks identified include interest rate risk, credit risk, liquidity risk, and foreign currency risk. Interest rate risk arises from fluctuations in market interest rates affecting cash holdings and finance facilities; mitigated by locking portions of cash into term deposits with maturity aligned to cash flow forecasts. Credit risk arises from counterparty defaults on cash, cash equivalents, and receivables; mitigated by placing cash with highly rated banks, monitoring receivables, and low credit risk on BARDA income receivables. Liquidity risk involves difficulty in raising funds to meet liabilities; managed by Board oversight of cash flow forecasts, ensuring sufficient cash flow before entering contracts, and potential capital raising if needed. Foreign currency risk arises from exposure to multiple currencies (USD, GBP, EUR, NZD, etc.); mitigated by holding cash in various currencies and using foreign exchange forward contracts on an ad hoc basis. The Company maintains a low debt level and manages capital structure to maximize shareholder return and maintain flexibility for strategic investments. | Financial risks identified include foreign currency risk, interest rate risk, credit risk, and liquidity risk. Foreign currency risk arises from fluctuations in exchange rates affecting cash, receivables, and payables denominated in multiple currencies. The company mitigates this by holding cash and equivalents in various currencies and matching currency inflows and outflows. Interest rate risk relates to fluctuations in market interest rates impacting cash holdings and equipment finance facilities; the company manages this by placing cash in term deposits with varying maturities aligned to cash flow needs. Credit risk arises from potential counterparty defaults on receivables and cash deposits; mitigated by placing cash with high credit-rated banks and monitoring receivables aging and expected credit losses. Liquidity risk arises if the company cannot meet financial liabilities; managed by the Board through regular review of cash flow forecasts, ensuring sufficient cash to meet debts, and controlling commitments. Capital risk management aims to maintain an optimal capital structure to safeguard going concern status, with capital raising activities undertaken as needed. The company has equipment finance and short-term loan facilities with defined interest rates and repayment schedules, with covenants including maintaining minimum cash balances. |
| Compliance Risks | Compliance risks include adherence to a wide range of legal and regulatory requirements related to products, sales, health and safety, employment, and corporate governance. Failure to comply could negatively impact operations, customers, employees, and shareholders. The Company mitigates these risks through internal systems, processes, and monitoring, supported by dedicated teams in Quality Assurance, Regulatory Affairs, Medical Liaison, and Legal & Compliance. Compliance frameworks are evolving to address the increasing complexity of obligations. Additionally, the Company maintains strong corporate governance aligned with ASX Principles, a Code of Conduct, Whistleblower Policy, Diversity Policy, and Environment Policy. The Company also addresses modern slavery risks proactively with staff training and supply chain monitoring. | Compliance risks include regulatory approvals, legal requirements, and adherence to industry standards. The company operates in a highly regulated biotechnology and medical device environment requiring clinical trials and regulatory clearances such as FDA 510(k) approvals. Risks include uncertainty in obtaining and maintaining patent protection and proprietary rights. PolyNovo conducts animal testing only when required for regulatory approval under ethical standards and regulatory oversight. The company complies with environmental regulations and is committed to minimizing environmental impact, with certifications such as carbon neutrality for business operations. Corporate governance policies emphasize lawful, ethical, and responsible conduct, safeguarding integrity in reporting, and managing risk. The company has policies addressing modern slavery and ethical labor practices in operations and supply chains. Directors and officers are indemnified and insured against liabilities arising from their roles. The Board oversees risk management and compliance, with regular reviews of policies and governance practices. No contingent liabilities or legal contingencies were reported as of 30 June 2023. |


# Section 5: Corporate Governance

## S5.1: Board Composition
| Name | Position | Total Income |
| :---- | :---- | -----------: |
| Mr Swami Raote | Chief Executive Officer | US$1,523,944 |
| Mr Jan Gielen | Chief Financial Officer | US$371,954 |
| Dr David McQuillan | Chief Scientific Officer | US$424,157 |
| Mr Philip Scorgie | Chief Information Officer | US$253,614 |
| Mr David Williams | Non-executive Chairman | US$139,429 |

## S5.2: Internal Controls
| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Risk assessment procedures | PolyNovo employs a robust risk management framework appropriate to its size and commercial product development stage. The Group has a formal risk management policy and framework involving identification, assessment, and management of risks in the context of the Group's values, objectives, and strategies. The Board oversees the implementation and effectiveness of the risk management system. Key risks are identified and summarized with corresponding mitigation strategies. Financial risks such as interest rate risk, credit risk, liquidity risk, and foreign currency risk are managed through specific policies including cash flow forecasting, diversification of deposits, and use of foreign exchange forward contracts. The risk management framework aligns with the ASX Corporate Governance Council's Principles, specifically Principle 7, supported by the PolyNovo Risk Management Policy and other related policies. | PolyNovo has a formal risk management policy and framework involving identification, assessment, and management of risks in the context of the Group's values, objectives, and strategies. The Board oversees the implementation and reviews the effectiveness of the risk management system. The Group seeks to minimize exposure to risks impacting financial performance, growth, and survival in a cost-effective manner. The Board regularly reviews liquidity risk by monitoring undiscounted cash flow forecasts and actual cash flows provided by management to ensure the Group can meet its debts as they fall due. The Group uses a provision matrix based on historical credit loss experience adjusted for forward-looking factors and economic environment to assess expected credit losses on trade receivables. The Group conducts annual impairment assessment reviews of asset values, considering external factors such as changes in expected future processes, technology, and economic conditions to identify impairment indicators. The Group also assesses foreign currency risk exposure and manages interest rate risk by locking portions of cash into term deposits based on cash flow forecasts. The Board monitors capital risk to maintain an optimal capital structure and safeguard going concern status. |
| Control activities | Control activities include implementation of business continuity plans, confidentiality agreements with staff and third parties, access controls to key systems, and monitoring of access. The Company maintains product liability insurance and business interruption insurance. Compliance frameworks are evolving to support legal and regulatory obligations, supported by dedicated teams in Quality Assurance, Regulatory Affairs, Medical Liaison, and Legal & Compliance. Corporate governance policies include a Code of Conduct, Whistleblower Policy, Diversity Policy, Share Trading Policy, Environment Policy, and Modern Slavery Statement. The Board Charter, Audit and Risk Committee Charter, Remuneration and Nomination Committee Charter, and other policies underpin control activities. Financial controls include management of capital structure, cash flow forecasting, and monitoring of financial instruments. The Company also applies accounting policies consistent with Australian Accounting Standards and IFRS. | The Group implements control activities including compliance with Australian Accounting Standards, Corporations Act 2001, and ASX Corporate Governance Council Principles. Revenue recognition controls include assessment of new contracts, testing controls over initiation and recording of sales transactions, and verification of revenue recognition against delivery and contract terms in accordance with AASB 15. The Group applies a provision matrix for expected credit loss measurement on trade receivables. Depreciation and impairment policies are applied to plant, equipment, and intangible assets with regular reviews. The Group maintains a Directors' and Officers' Liability Insurance Policy and indemnifies Directors and Officers against liabilities arising from their roles, except for conduct involving lack of good faith. Share-based payment plans are used as part of remuneration and incentive structures. The Board approves capital management decisions and reviews liquidity risk management policies. The Group maintains foreign currency cash balances to reduce currency risk exposure. The Group uses term deposits to manage interest rate risk and cash flow requirements. |
| Monitoring mechanisms | Monitoring mechanisms include oversight by the Board of Directors and its committees, notably the Audit and Risk Committee chaired by a Non-Executive Director. The Board reviews policies and governance practices regularly. The Audit and Risk Committee Charter guides monitoring of corporate reports and risk management. The Board monitors liquidity risk through review of undiscounted cash flow forecasts and actual cash flows provided by management. Internal systems and processes support monitoring of legal, regulatory, and policy compliance. External audit is conducted by Ernst & Young, who perform audit procedures responsive to assessed risks and communicate significant findings and deficiencies to the directors. The Board also receives declarations from auditors regarding independence and non-audit services. The Remuneration Committee oversees remuneration consultants and frameworks. The Company maintains ongoing review of credit risk exposure and impairment assessments. The Board monitors capital management and the need for additional equity based on cash flow forecasts. | The Board is responsible for overseeing the risk management system implementation and reviews its effectiveness. The Audit and Risk Committee monitors financial risks including liquidity, credit, interest rate, and foreign currency risks. The Board regularly reviews undiscounted cash flow forecasts and actual cash flows to monitor liquidity risk. The Group conducts annual impairment assessments of intangible and other assets. The external auditor, Ernst & Young, performs audits including assessment of internal controls relevant to the audit and communicates significant deficiencies to the directors. The Remuneration Committee governs variable pay arrangements linked to performance. The Board reviews corporate governance policies in reference to the ASX Corporate Governance Council's eight Principles. The Group monitors trade receivables and expected credit losses on an ongoing basis. The Board monitors capital structure and funding needs based on actual and forecast cash flows provided by management. |
| Identified material weaknesses or deficiencies | N/A | N/A |
| Effectiveness | Management assesses the overall effectiveness of internal controls through the Board's review of the risk management system's implementation and effectiveness. The Board is responsible for ensuring internal controls are sufficient to prepare financial reports free from material misstatement. The external auditor's report expresses an unqualified opinion on the financial report, indicating no material misstatements were found and no significant deficiencies in internal control were reported. The Board and Audit and Risk Committee conclude that the internal control system is adequate and effective in managing risks and ensuring compliance with applicable laws and standards. | Management and the Board assess the internal control system as effective in enabling preparation of financial reports that give a true and fair view and are free from material misstatement, whether due to fraud or error. The Board reviews and assesses the effectiveness of the risk management system implementation. The external auditor's opinion states the financial report is in accordance with the Corporations Act 2001, giving a true and fair view and complying with Australian Accounting Standards. The auditor communicates any significant deficiencies in internal control identified during the audit to the directors. The Group's internal controls over revenue recognition were tested and found operating effectively as part of the audit procedures. The Board and Audit and Risk Committee provide oversight to ensure adequacy and compliance of internal controls. |


# Section 6: Future Outlook

## S6.1: Strategic Direction

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Mergers and Acquisition | The 2024 annual report does not mention any mergers, acquisitions, bolt-on deals, or strategic investments. The company focuses on organic growth, geographic expansion, and partnerships for product development and distribution but does not disclose any M&A activity or plans. | PolyNovo's 2023 annual report does not explicitly mention any mergers, acquisitions, bolt-on deals, or strategic investments. The company focuses on organic growth, expanding market presence in new geographies such as Canada, Hong Kong, India, Spain, and France, and exploring potential partnerships in China and Japan. The report highlights transformational M&A possibilities in plastic and reconstructive surgery-oriented businesses but does not detail any active M&A transactions or specific acquisition targets. |
| New technologies | The company is advancing technology innovation through increased R&D investment, expanding the NovoSorb product range to include additional sizes and thicknesses, and developing new iterations such as thicker and thinner versions of NovoSorb BTM and MTX. They are also developing particulate variants of NovoSorb MTX for soft tissue reconstruction. The Plastic and Reconstructive device program under the NovoSorb SynTrix platform leverages hernia device development for other tissue reinforcement products. The company is collaborating with Beta Cell Technologies on a NovoSorb Dermal Beta-Cell Implant for Type 1 Diabetes treatment, with promising early human trial results expected to be published in late 2024. They plan to establish a new co-located R&D lab and innovation center. Strategic technology partnerships include working with surgeons and academia for clinical insights and product development. The company also added SUPRATHEL via distribution to their product portfolio to offer a broader range of wound care solutions. Investment in information technology and innovation programs to support sales and clinical education is ongoing. | PolyNovo is investing significantly in R&D to support new product development and faster commercialization, with FY23 R&D expenditure of $7.4 million, up from $5.7 million in FY22. The company focuses on its proprietary NovoSorb bioabsorbable polymer platform, which supports a range of graftable and implantable medical devices. Key technology initiatives include the development and FDA 510(k) clearance of NovoSorb MTX, expanding applications in soft tissue regeneration and complex wounds. Clinical trials are ongoing for NovoSorb SynPath targeting diabetic foot ulcers and chronic wounds, with pivotal BARDA-funded trials for full thickness burns underway. The company is designing a new manufacturing facility emphasizing flexibility, modularity, and automation to scale production approximately fivefold. Strategic technology partnerships and alliances with global category leaders and academia support clinical and health economics evidence generation. The technology platform's flexibility allows configurations in foams, filaments, films, coatings, fibers, and plastic structures, enabling applications in burns, trauma, hernia repair, breast reconstruction, orthobiologics, and delivery of therapeutics. |
| Organisational Restructuring | The company expanded its executive leadership team in FY24 with several new appointments including Chief Medical Officer, Chief People Officer, President Asia Pacific, and General Counsel & Company Secretary, and promoted the President North America. The Remuneration Committee undertook a comprehensive review of remuneration policies, developing an executive Remuneration Policy to support motivation and retention of talent, with benchmarking against industry data and refreshed KPIs for FY25. The company emphasizes talent attraction and retention, providing employee development programs including online learning platforms, conference attendance, and performance planning. Diversity and inclusion are promoted with updated Diversity Policy and gender pay equity analysis. Health and safety initiatives were enhanced with strong engagement and zero lost time injuries in FY24. The company introduced the PolyNovo Promise to reinforce culture and values. Overall, organizational changes focus on building a global, patient-centric culture and strengthening leadership to support global growth. | PolyNovo increased its workforce from 152 to 218 employees in FY23, with significant expansion of the U.S. sales team from 54 to 93 people and onboarding of sales professionals in new markets including Hong Kong and India. The company has invested in building clinical capabilities and R&D teams to drive innovation and evidence generation. New senior management appointments include a Chief Executive Officer (appointed July 2022), Chief Technical and Scientific Officer (appointed September 2022), and Chief Information Officer (appointed May 2023). The company has expanded office space and is designing a new co-located manufacturing, R&D, and office facility to support scale and operational efficiency. Talent management initiatives include access to online learning platforms, appraisal and development programs, targeted educational programs, and mentorship. PolyNovo maintains a strong focus on diversity and inclusion, monitoring company-wide diversity profiles and fostering an inclusive workplace culture. Senior management remuneration policies link compensation to performance milestones, including clinical trials, product sales, and production targets, with short-term and long-term incentive plans designed to encourage high-quality performance and retention. |


## S6.2: Challenges and Uncertainties

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| Economic challenges such as inflation, recession risks, and shifting consumer behavior that could impact revenue and profitability. | PolyNovo Limited faces economic challenges including inflation and rising interest rates which have increased costs across all markets, notably wages and salaries. The company manages interest rate risk through term deposits and cash flow forecasting to mitigate fluctuations in interest income and expenses. Foreign currency risk is significant due to expenses in multiple currencies (USD, GBP, EUR, NZD), and the company uses cash holdings in various currencies and forward contracts to manage this exposure. Supply chain risks exist due to reliance on single manufacturing sites and key suppliers, with potential disruptions impacting production and costs. The company actively updates cash flow forecasts to manage the impact of higher inflation and interest costs and maintains business interruption insurance and diversification strategies. Macroeconomic uncertainties such as global market conditions and currency fluctuations could impact revenue and profitability, especially as the company expands into new geographic markets including India, Japan, China, and Brazil. | PolyNovo Limited faces economic challenges including inflation and rising interest rates which have increased costs across all markets, notably wages and salaries. The company manages foreign currency risk due to exposure to multiple currencies (USD, NZD, EUR, CAD, INR, GBP, SGD) which can impact financial results through exchange rate fluctuations. The Group updates cash flow forecasts to incorporate the impact of rising costs and maintains discretion in managing cash outflows to mitigate these pressures. Liquidity risk is managed by monitoring cash flow forecasts and ensuring sufficient funds to meet financial liabilities. Interest rate risk affects cash holdings and equipment finance facilities, with the Group managing this by locking cash into term deposits. The macroeconomic environment, including market interest rates and currency exchange rates, introduces uncertainties that could affect revenue and profitability. Additionally, the Group's growth and expansion plans require ongoing capital management, including potential equity raises, to support operations and investments. The biotechnology sector's inherent volatility and high risk, including the lengthy and uncertain clinical trial process, also contribute to economic uncertainties impacting business performance. |
| Competitive pressures from both established industry players and new, disruptive market entrants that the company faces. | PolyNovo faces competitive pressures from increased competition that risks loss of market share, particularly if the company fails to innovate beyond its current core offerings. There is a risk that medical advancements could supersede their products, leading to alternative treatments. The company operates in markets with established industry players and new entrants, requiring continuous product innovation and strategic review of product development plans considering market dynamics and technological advancements. The company is the category leader in difficult burns in several developed markets but aims to expand leadership in other indications and geographies. Competitive threats include the need to maintain and grow market share in the U.S., U.K., Germany, and emerging markets like India and Hong Kong. The company invests in R&D, professional education, and regulatory approvals to sustain competitive advantage and is open to alliances to strengthen its position. Technological disruption and evolving industry dynamics necessitate ongoing innovation and market expansion to counter competitive threats. | PolyNovo operates in a competitive medical device and biotechnology industry where it faces pressures from established players and potential new entrants. The company is expanding its product portfolio and geographic reach, entering new markets such as India, Canada, Hong Kong, Spain, and France, and exploring entry into large markets like China and Japan, which may intensify competition. Technological innovation and surgeon-led insights drive product development, but the company must continuously innovate to maintain and grow its market position. The company acknowledges the need for strategic partnerships and alliances to accelerate commercialization and expand indications, indicating competitive dynamics that require collaboration and agility. Market competition includes the need to secure regulatory approvals (e.g., FDA 510(k) clearances) and to build clinical and health economics evidence to support product adoption. The expansion of sales teams and customer accounts, especially in the U.S., reflects efforts to counter competitive threats. The company also faces industry dynamics such as evolving clinical needs, surgeon preferences, and the emergence of new applications for its technology, requiring ongoing investment in R&D and manufacturing capacity to stay competitive. |


## S6.3: Innovation and Development Plans

| Perspective | 2024 Report | 2023 Report |
| :---- | :---- | :---- |
| R&D investments, with a focus on advancing technology, improving products, and creating new solutions to cater to market trends | PolyNovo Limited increased its research and development expenses by 47.1% to $10.9 million in FY24, reflecting heightened activity in research and commercialisation of new products. The company focuses on advancing its patented bioabsorbable polymer technology NovoSorb, developing novel medical devices for tissue repair including particulate forms for irregular wound sites, antimicrobial variants, superficial burns products, and synthetic allograft products. Investments include expanding the NovoSorb BTM product range with larger sizes and varied thicknesses, and developing the NovoSorb SynTrel platform for plastics and reconstructive device products such as hernia repair meshes. The company is also constructing a third manufacturing facility with a co-located R&D lab and innovation centre, expected operational by December 2025, supported by a $2 million Victorian Government grant. Clinical evidence building and professional education programs like 'Science of Complex Wound Management' are key initiatives. BARDA funding supports pivotal clinical trials for severe thermal burns, with $11.15 million revenue recognized in FY24. Additional FDA 510(k) submissions for product range expansion are planned in 2024. Overall, R&D investments target technology advancement, product improvement, and new solution creation aligned with market trends and global expansion plans. | PolyNovo Limited increased its R&D expenditure by 29.3% to $7.4 million in FY23, focusing on advancing technology, improving products, and commercialising new solutions. Key investment areas include the in-house breast development program leveraging hernia device experience, expansion of the NovoSorb product range including BTM and MTX, and clinical trials such as the U.S. BARDA pivotal trial for full thickness burns and a randomized control trial for diabetic foot ulcers using NovoSorb SynPath. Capital investments included cleanroom upgrades and new manufacturing/process equipment, partly funded by a $500k Victorian State Government grant. The company also invested in expanding manufacturing capabilities with a new facility design underway to support a fivefold increase in production capacity. R&D efforts are supported by surgeon-led innovation, clinical evidence generation, and partnerships with academia and global leaders. Regulatory submissions for product expansions are planned, including additional FDA 510(k) clearances in 2023 and 2024. Employee-related expenses increased to support growth in sales, marketing, production, R&D, and quality teams. |
| New product launches, emphasizing the company's commitment to continuously introducing differentiated products | In FY24, PolyNovo launched NovoSorb MTX with a full market release in the U.S., following FDA 510(k) clearance in September 2022 and a limited market release starting April 2023. NovoSorb MTX complements NovoSorb BTM, offering broad applicability for single-stage grafting in burns, chronic, and surgical wounds, and is gaining adoption among vascular surgeons for diabetic patients and complex wound management. Multiple variants of NovoSorb MTX, including a particulate form for soft tissue reconstruction, are planned to drive further adoption. The company also added SUPRATHEL, an epidermal skin substitute with strong clinical evidence and market leadership in Europe, to its product suite for Australia, New Zealand, and the U.K., expanding treatment options across the continuum of complex wound care. Product innovations emphasize versatility, robustness against infection, and surgeon autonomy, with market differentiation achieved through superior patient outcomes, cost-effectiveness, and expanding indications beyond burns into trauma, diabetic limb preservation, and reconstructive surgery. The company continues to leverage surgeon insights to drive new indications and product pipeline development. | In FY23, PolyNovo launched NovoSorb MTX, a major product innovation for soft tissue regeneration, receiving FDA 510(k) clearance in September 2022 and commencing limited market release in the U.S. in April 2023. NovoSorb MTX complements the flagship NovoSorb BTM by providing a foam-only product without a sealing membrane, suitable for partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, and surgical and trauma wounds, expanding the addressable U.S. market by an estimated AUD $500 million. The company also expanded geographic market presence by launching products in Hong Kong, Canada, India, Spain, and France, with early impressive sales. NovoSorb SynPath is undergoing clinical trials for diabetic foot ulcers, with plans for U.S. market launch post-trial completion. The product portfolio expansion strategy includes further 510(k) submissions to support the BTM and MTX ranges, and ongoing development of implantable applications such as hernia and breast reconstruction devices. Market differentiation is driven by surgeon-led insights, clinical evidence, and the unique properties of the proprietary NovoSorb polymer platform. |
